Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 2/20 | 0.43 |
| ▸ | SKP1 | P63208 | 2/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000217 | 0.88 | HRH4 (0.55) | HRH4 | |
| SCHEMBL3001488 | 0.86 | HRH4 (0.55) | HRH4NR1H2MAPTCKS1BSKP1 | |
| SCHEMBL2992981 | 0.83 | HRH4 (0.46) | HRH4GPR119NR1H2PIK3CALRRK2 | |
| SCHEMBL2533790 | 0.82 | HRH4 (0.59) | HRH4 | |
| SCHEMBL2803382 | 0.81 | NR1H2 (0.57) | HRH4NR1H2 | |
| SCHEMBL3007326 | 0.81 | HRH4 (0.51) | HRH4NR1H2MAPTMAP4K4 | |
| SCHEMBL15254483 | 0.80 | HRH4 (0.51) | HRH4 | |
| SCHEMBL3001496 | 0.78 | HRH4 (0.58) | HRH4 | |
| SCHEMBL14922693 | 0.78 | HRH4 (0.58) | HRH4 | |
| SCHEMBL2515479 | 0.77 | HRH4 (0.50) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2010075270-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | INCYTE CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173901-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | HRH4 1/4885GPR119 1181/4885NR1H2 311/4885 |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | HRH4 1/4885GPR119 1181/4885NR1H2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.